Nicotine dependence - Studies with a laboratory model

被引:120
作者
Malin, DH [1 ]
机构
[1] Univ Houston Clear Lake, Houston, TX 77058 USA
关键词
nicotine dependence; nicotine abstinence syndrome; nicotine withdrawal; physical dependence; preclinical models; nicotinic antagonists; rat;
D O I
10.1016/S0091-3057(01)00699-2
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Simple, rapid preclinical models of nicotine physical dependence and abstinence syndrome are needed to identify underlying neurobiological mechanisms and screen potential therapies. One such model induces dependence by 7 days of continuous subcutaneous nicotine infusion in the rat. Abstinence is initiated through termination of infusion or injection of nicotinic antagonist drugs. The result is an abstinence syndrome involving a pattern of behaviors somewhat resembling opiate abstinence in the rat as well as weight gain and depressed locomotor activity. The model has met a number of validity criteria and its essential features have been replicated in several laboratories, Several research groups have modified or extended the model by measuring emotional/motivational changes associated with nicotine abstinence such as conditioned aversion, intracranial self-stimulation (ICSS) thresholds and the startle response. Dependence models have been used to identify neurobiological systems that contribute to nicotine dependence, particularly endogenous opiate systems and the mesolimbic dopamine pathway. It is hypothesized that these different systems contribute to different behavioral aspects of nicotine abstinence syndrome. Increasingly used as a preclinical screening tool, the model has proved sensitive to various abstinence-alleviating therapeutic approaches, including some with already demonstrated clinical effectiveness. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:551 / 559
页数:9
相关论文
共 83 条
  • [51] Nicotine abstinence syndrome precipitated by central but not peripheral hexamethonium
    Malin, DH
    Lake, JR
    Schopen, CK
    Kirk, JW
    Sailer, EE
    Lawless, BA
    Upchurch, TP
    Shenoi, M
    Rajan, N
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1997, 58 (03) : 695 - 699
  • [52] NALOXONE PRECIPITATES NICOTINE ABSTINENCE SYNDROME IN THE RAT
    MALIN, DH
    LAKE, JR
    CARTER, VA
    CUNNINGHAM, JS
    WILSON, OB
    [J]. PSYCHOPHARMACOLOGY, 1993, 112 (2-3) : 339 - 342
  • [53] THE NICOTINIC ANTAGONIST MECAMYLAMINE PRECIPITATES NICOTINE ABSTINENCE SYNDROME IN THE RAT
    MALIN, DH
    LAKE, JR
    CARTER, VA
    CUNNINGHAM, JS
    HEBERT, KM
    CONRAD, DL
    WILSON, OB
    [J]. PSYCHOPHARMACOLOGY, 1994, 115 (1-2) : 180 - 184
  • [54] RODENT MODEL OF NICOTINE ABSTINENCE SYNDROME
    MALIN, DH
    LAKE, JR
    NEWLINMAULTSBY, P
    ROBERTS, LK
    LANIER, JG
    CARTER, VA
    CUNNINGHAM, JS
    WILSON, OB
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1992, 43 (03) : 779 - 784
  • [55] FMRF-NH2-LIKE MAMMALIAN OCTAPEPTIDE - POSSIBLE ROLE IN OPIATE DEPENDENCE AND ABSTINENCE
    MALIN, DH
    LAKE, JR
    HAMMOND, MV
    FOWLER, DE
    ROGILLIO, RB
    BROWN, SL
    SIMS, JL
    LEECRAFT, BM
    YANG, HYT
    [J]. PEPTIDES, 1990, 11 (05) : 969 - 972
  • [56] Nicotine abstinence syndrome precipitated by the competitive nicotinic antagonist dihydro-β-erythroidine
    Malin, DH
    Lake, JR
    Upchurch, TP
    Shenoi, M
    Rajan, N
    Schweinle, WE
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1998, 60 (03) : 609 - 613
  • [57] SUBCUTANEOUS INJECTION OF AN ANALOG OF NEUROPEPTIDE-FF PRECIPITATES MORPHINE ABSTINENCE SYNDROME
    MALIN, DH
    LAKE, JR
    ARCANGELI, KAR
    DESHOTEL, KD
    HAUSAM, DD
    WITHERSPOON, WE
    CARTER, VA
    YANG, HYT
    PAL, B
    BURGESS, K
    [J]. LIFE SCIENCES, 1993, 53 (17) : PL261 - PL266
  • [58] AURICULAR MICROELECTROSTIMULATION - NALOXONE-REVERSIBLE ATTENUATION OF OPIATE ABSTINENCE SYNDROME
    MALIN, DH
    MURRAY, JB
    CRUCIAN, GP
    SCHWEITZER, FC
    COOK, RE
    SKOLNICK, MH
    [J]. BIOLOGICAL PSYCHIATRY, 1988, 24 (08) : 886 - 890
  • [59] Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome
    Malin, DH
    Lake, JR
    Lin, A
    Saldaña, M
    Balch, L
    Irvin, MLL
    Chandrasekara, H
    Alvarado, CL
    Hieda, Y
    Keyler, DE
    Pentel, PR
    Ennifar, S
    Basham, LE
    Naso, R
    Fattom, A
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2001, 68 (01) : 87 - 92
  • [60] The nitric oxide synthesis inhibitor nitro-L-arginine (L-NNA) attenuates nicotine abstinence syndrome in the rat
    Malin, DH
    Lake, JR
    Shenoi, M
    Upchurch, TP
    Johnson, SC
    Schweinle, WE
    Cadle, CD
    [J]. PSYCHOPHARMACOLOGY, 1998, 140 (03) : 371 - 377